Stroke's Gait Pattern Modifications of Induced by Repeated BTI

Improvement of Chronic Stroke Patients Gait Pattern Following Repetitive Multifocal Botulinum Toxin Injection Sessions in Paretic Lower Limb: an Observational Study.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01973023

Enrollment

Registered

2013-10-31

Start date

2013-07-31

Completion date

2014-01-31

Last updated

2016-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effect of Repeated Botulinum Toxin Injection on Gait Pattern in Stroke Patients

Keywords

botulinum toxin injection, stroke, 3D motion analysis, gait pattern

Brief summary

Chronic stroke patients exhibit gait pattern alterations which are mainly due to spasticity and treated with repetitive multifocal botulinum toxin injection(BTI). Several studies demonstrated that single BTI-session in a single muscle of paretic lower limb(LL) improved kinematic gait parameters(GP) but surprisingly none of them assessed the effects of repetitive multifocal BTI on patient's gait pattern and their duration. The aim was to evaluate the impact of repetitive multifocal BTI-sessions on GP of chronic stroke patients. To that end, gait of patients has been compared using 3D-gait analysis after at least 2 consecutive BTI sessions.

Detailed description

All the patients will be tretaed with BTI . these injections will be performed under electrical stimulation control (\ 5mA). The dose, the number of site of injection per muscle is at the discretion of the physician according to patients' needs and physicians' routine clinical practice. The dilution the most commonly used will depend on the type of BoNT-A (BOTOX®, XEOMIN® or DYSPORT®) and was 100 U for 2.5ml (BOTOX® and XEOMIN®) or 500 U for 2.5 ml (Dysport®).

Interventions

OTHERMotion analysis

Motion analysis was used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection

Study design

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

-\>18 years * a single hemispheric cerebral vascular lesion more than 6 months previously * able to walk 10 meters without any assistance * having benefited of at least 2 consecutive BTI sessions, second 3D gait analysis performed at least 3 months after the last BTI.

Exclusion criteria

* patient's refusal to participate to the study * Inability to read the selected text * Inability to cooperate * No affiliation to social security

Design outcomes

Primary

Measure	Time frame	Description
kinematics gait parameters	3h	peak knee flexion in swing phase(°)

Secondary

Measure	Time frame	Description
spatiotemporal gait parmeters	3h	gait velocity(m/s)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026